US-based advanced respiratory failure therapies provider, ALung Technologies has secured CE Mark approval for its next-generation Hemolung XG4 cartridge and catheter kits.
The approval enables the company to launch the new kits in select European markets from July.
The devices are used as part of the Hemolung Respiratory Assist system to provide respiratory dialysis, a minimally invasive extracorporeal CO2 removal therapy, as an alternative or supplement to mechanical ventilation for patients suffering from acute respiratory failure.
ALung chairman Peter DeComo said: "These new kits were developed at the request of our growing user base who identified pre-connected tubing as its most desired feature.
"This update is a major step forward in making Hemolung therapy even easier to implement, and we are pleased to make it available to our customers."
Hemolung XG4 cartridge kit features a fully pre-connected circuit that accelerates the initiation of Hemolung therapy by reducing several steps from the setup process.
In addition, the kits have been packaged in sterile plastic trays that are easy to handle at the bedside. In the Hemolung catheter kit, the company packaged all insertion accessories with the catheter in one tray to help improve usability under sterile conditions.
ALung is set to display Hemolung XG4 kits at the sixth International Congress on ECMO in Paris, France, which will be held from 25- 26 June.
Image: The new Hemolung XG4 cartridge and catheter kits are designed to further simplify initiation of respiratory dialysis. Photo: courtesy of ALung Technologies.
